

**DCF Psychotropic Medication Advisory Committee**  
**MINUTES**  
**June 3, 2016 1:00 PM**

1. The meeting was called to order by Dr. Harris at 1:05PM.
2. Set date/time of next meeting: The next meeting is scheduled for September 9, 2016 (September 5<sup>th</sup> is the Friday of Labor Day weekend) from 1pm – 2:30pm at 500 Enterprise Drive, Rocky Hill, CT 06067. Please inquire as to room location on 3<sup>rd</sup> floor upon arrival.
3. Medication Therapeutic Class Review:  
Antidepressants; Protocol review, Approved drug list review, Pregnancy classification review, Max dose review, Utilization data review. FDA warnings (if any). In addition, the protocol was compared to the LA County protocol (updated last fall).
  - Noted and discussed that the DCF PMAC recommended maximum daily doses (especially for tricyclics) are more conservative than the LA County recommended maximum daily doses.
  - No changes recommended to the protocol. Several formatting changes were recommended after review and discussion.
    - Pregnancy category note: make font larger and move to the top of the page.
    - Noted categories and/or titles now carry over to the top of the next page when needed.
  - No FDA warnings over the past year for this class of medication.

Approved drug list consideration:

-None requested for this class of medication.

Utilization data review:

- Utilization for this class of medications was presented, reviewed and discussed in detail. Data was trended by age, gender and ethnicity. It was noted that there is a spike in use of this class of medications at age 11. No other trends noted.
- An increased utilization in minorities was noted.
- For children <=10yrs old only 1 was on 2 medications. No trends noted for this age group.

Review of meds denied for the Approved Drug List: each medication was reviewed and discussed in detail.

SUMMARY:

-nefazodone: No new information available. No change to approved drug list status recommended.

-paroxetine: Results of 1 new study from last fall was presented.

Conclusion; paroxetine is ineffective and unsafe. No change to approved drug list status recommended.

-trazodone XR: No new information available. No change to approved drug list status recommended.

-vilazodone: No posted results from the previously presented study however recruitment is currently underway for 3 new studies. No change to approved drug list status recommended.

Full monograph review: LA injectables: aripiprazole (both formulations), paliperidone.

Safety profile statement: olanzapine AL injection

- The full monographs as well as the safety profile statement were presented, reviewed and discussed in detail.
- RECOMMENDATIONS:
  - Add paliperidone LA inj. to the approved drug list limited to use in adolescents only. Dosing recommendation is per package insert. Required monitoring recommended to be the same as for other AL psychotropic medications. Also recommend baseline requirements need to be established.
  - Although there are no studies for children or adolescents it is noted that the safety profile mimics the po formulation. Add both LA formulations of aripiprazole restricted to adolescents only. Recommended maximum dose same as adults. Also recommended baseline requirements need to be established.

4. Minutes of the May 2016 meeting were reviewed and approved with several minor changes.
5. Announcements: Drug monographs can now be added to the DCF PMAC web site.
6. Roumen Nikolov MD of Solnit Children's Center arrived at 1:50pm.
  - The Committee welcomed Dr. Nikolov and a discussion took place regarding:
    - The history of the DCF PMAC
    - The work that the PMAC has accomplished such as
      - Protocol development
      - Approved drug list
      - Maximum dosing guidelines
      - Tracing medication use by class
    - The possibility of coordinating efforts in the above areas as well as ADR reporting was discussed.
7. Adjournment: Dr. Harris will be resigning state service effective 30 June 2016. The entire committee expressed thanks to Dr. Harris for all the hard work she has put into the PMAC as its Chairperson. Adjourned 2:25PM.